Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Locally advanced or metastatic breast cancer~* HER2-negative and hormone receptor-positive status (common breast cancer classification tests)~* Postmenopausal woman~* A tumor sample must be shipped to a Novartis designated laboratory for identification of biomarkers (PI3K activation status)~* Progression or recurrence of breast cancer while on or after aromatase inhibitor treatment~* Measurable disease or non measurable disease bone lesions in the absence of measurable disease as per RECIST 1.1~* Adequate bone marrow and organ function defined by laboratory values~Key Exclusion Criteria:~* Previous treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitor or fulvestrant~* More than one prior chemotherapy line for metastatic disease~* Symptomatic brain metastases~* Increasing or chronic treatment (\> 5 days) with corticosteroids or another immunosuppressive agent~* Active heart (cardiac) disease as defined in the protocol~* Certain scores on an anxiety and depression mood questionnaires

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BKM120 100mg + Fulvestrant (Type: EXPERIMENTAL): BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
- Placebo + Fulvestrant (Type: PLACEBO_COMPARATOR): BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).